Velan Capital Investment Management
Velan Capital Investment Management reported 50 stocks worth $163M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are PRAX (18.2%), MPLT (10.8%) and STRO (10.4%). Compared with Q1 2026, the fund opened new positions in CCCC, ADMA and RNTX, added to IMMX, TARA and EVMN, trimmed PRAX, ABVX and TENX and sold out of KZIA, ARWR and DSGN.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  PRAX Praxis Precision Medicines I | $29.7M | 18.2% | 89K | −12K (−12%) | 8 of 8 | |
| 2 |  MPLT Maplight Therapeutics Inc | $17.7M | 10.8% | 493K | No change | 3 of 8 | |
| 3 |  STRO Sutro Biopharma Inc | $17M | 10.4% | 512K | No change | 3 of 8 | |
| 4 |  IMMX Immix Biopharma Inc | $11.2M | 6.8% | 1.1M | +345K (+47%) | 5 of 8 | |
| 5 |  TARA Protara Therapeutics Inc | $10.9M | 6.7% | 2.8M | +10K (+0%) | 8 of 8 | |
| 6 |  ABVX Abivax SA | $8.7M | 5.4% | 66K | −11K (−15%) | 4 of 8 | |
| 7 |  TENX Tenax Therapeutics Inc | $8M | 4.9% | 550K | −33K (−6%) | 8 of 8 | |
| 8 |  AVR Anteris Technologies Global | $6.9M | 4.2% | 700K | No change | 2 of 8 | |
| 9 |  EDSA Edesa Biotech Inc | $6.7M | 4.1% | 828K | No change | 6 of 8 | |
| 10 |  EVMN Evommune Inc | $6M | 3.7% | 451K | +5,000 (+1%) | 3 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
TENX Tenax Therapeutics Inc | Call | $1000K | 69K | +68,700 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Velan Capital Investment Management 13F FAQ
What does Velan Capital Investment Management own?
Velan Capital Investment Management reported 50 stocks worth $163M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are PRAX (18.2%), MPLT (10.8%) and STRO (10.4%). The table above lists every position in the filing (the top 10 without an account).
What did Velan Capital Investment Management buy and sell in Q2 2026?
Compared with Q1 2026: 6 new positions, 10 added to, 11 trimmed and 5 sold out. New positions include CCCC, ADMA and RNTX. It sold all of KZIA, ARWR and DSGN.
When will Velan Capital Investment Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Velan Capital Investment Management's portfolio worth?
The Q2 2026 filing reports $163M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.